Who are Paclitaxel (Taxane)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (Pac), Abraxane (Induction), Docetaxel/Paclitaxel, Nab-paclitaxel/Paclitaxel, Paclitaxel (X), Nab-paclitaxel （neoadjuvant）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-taxane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paclitaxel (Taxane) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel (Taxane) (Paclitaxel (Taxane)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane (microtubule-stabilizing agent). Area: Oncology.

phase 3 Taxane (microtubule-stabilizing agent) β-tubulin / microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel (Taxane) (Paclitaxel (Taxane)) — Eli Lilly and Company. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel (Taxane) TARGET	Paclitaxel (Taxane)	Eli Lilly and Company	phase 3	Taxane (microtubule-stabilizing agent)	β-tubulin / microtubules
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Abraxane (Induction)	Abraxane (Induction)	Celgene	phase 3	Microtubule stabilizer (taxane)	β-tubulin / microtubules
Docetaxel/Paclitaxel	Docetaxel/Paclitaxel	Ono Pharmaceutical Co. Ltd	phase 3	Taxane (microtubule-stabilizing chemotherapy)	β-tubulin / microtubules
Nab-paclitaxel/Paclitaxel	Nab-paclitaxel/Paclitaxel	BioNTech SE	phase 3	Microtubule stabilizer / Taxane	β-tubulin / Microtubules
Paclitaxel (X)	Paclitaxel (X)	Merck Sharp & Dohme LLC	phase 3	Taxane; microtubule stabilizer	β-tubulin / microtubules
Nab-paclitaxel （neoadjuvant）	Nab-paclitaxel （neoadjuvant）	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Microtubule stabilizer / Taxane	β-tubulin / Microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane (microtubule-stabilizing agent) class)

Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel (Taxane) — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-taxane. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab